Molekulargenetischer Nachweis minimaler Resterkrankung (minimal residual disease, MRD) bei Kindern mit akuter lymphoblastischer Leukämie

Zusammenfassung

Die Behandlung der akuten lymphatischen Leukämie (ALL) erlaubt heute im Kindes- und Jugendalter eine Heilungsrate von über 80%. Der Nachweis von minimaler Resterkrankung (minimal residual disease, MRD) mittels molekulargenetischer Methoden eröffnet im Vergleich zu konventionellen klinischen und biologischen Parametern deutlich sensitivere Ansätze, um das individuelle Therapieansprechen zu beurteilen. Hier sollen die molekularen Grundlagen und die technische Entwicklung im Kontext der BFM-Studiengruppe dargestellt werden.

Abstract

The treatment of acute lymphoblastic leukemia (ALL) in childhood and adolescence achieves nowadays cure rates of more than 80%. The detection of minimal residual disease (MRD) via moleculargenetic methods provides – in comparison with conventional clinical and biological parameters – much more sensitive approaches to monitor individual treatment response. Here we will discuss the molecular background and technical developments in the framework of the BFM-study group.

Schlüsselwörter

Akute lymphoblastische Leukämie (ALL) - Minimale Resterkrankung (MRD) - Berlin-Frankfurt-Münster (BFM) Studiengruppe - Risikostratifizierung - Therapieansprechen

Key words

acute lymphoblastic ­leukemia (ALL) - minimal residual disease (MRD) - Berlin-Frankfurt-Münster (BFM) study group - risk-group stratification - treatment response

• Literatur

• 1 Bartram CR. Genetische Grundlagen der Kanzerogenese. In: Bartram CR, Hiddemann W. Hrsg. Die Onkologie. 2. Aufl. Springer; Heidelberg: 2010: 67-127
• 2 Brüggemann M, Schrauder A, Raff T et al. European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL); International Berlin-Frankfurt-Münster Study Group (I-BFM-SG) . Standardized MRD quantification in European ALL trials: proceedings of the second international symposium on MRD assessment in Kiel, Germany, 18–20 September 2008. Leukemia 2010; 24: 521-535
• 3 Brüggemann M, Raff T, Flohr T et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006; 107: 1116-1123
• 4 Conter V, Bartram CR, Valsecchi MG et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010; 115: 3206-3214
• 5 Flohr T, Schrauder A, Cazzaniga G et al. International BFM Study Group . (I-BFM-SG). Minimal residualdisease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008; 22: 771-782
• 6 Hansen-Hagge TE, Yokota S, Bartram CR. Detection of minimal residual disease in acute lymphoblastic leukemia by in vitro amplification of rearranged T-cell receptor delta chain sequences. Blood 1989; 74: 1762-1767
• 7 van Dongen JJM, Langerak AW, Brüggemann M et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T cell receptor gene recombination in suspect lymphoproliferations: Report of the Biomed-2 Concerted Action BMH4-CT98-393. Leukemia 2003; 17: 2257-2317
• 8 Möricke A, Reiter A, Zimmermann M et al. German-Austrian-Swiss ALL-BFM Study Group . Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2 169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008; 111: 4477-4489
• 9 Möricke A, Reiter A, Zimmermann M et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 2010; 24: 265-284
• 10 Nakao M, Janssen JWG, Flohr T et al. Rapid and Reliable Quantification of Minimal Residual Disease in Acute Lymphoblastic Leukemia Using Rearranged Immunoglobulin and T-Cell Receptor Loci by LightCycler Technology. Cancer Research 2000; 60: 3281-3289
• 11 Pongers-Willemse MJ, Verhagen OJ, Tibbe GJ et al. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia 1998; 12: 2006-2014
• 12 Pongers-Willemse MJ, Seriu T, Stolz F et al. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 110-118
• 13 Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166-178
• 14 Reiter A, Schrappe M, Ludwig WD et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994; 84: 3122-3133
• 15 Schrappe M, Valsecchi MG, Bartram CR et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood 2011; 118: 2077-2084
• 16 Stow P, Key L, Chen X et al. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood 2010; 115: 4657-4663
• 17 van der Velden VH, Cazzaniga G, Schrauder A et al. European Study Group on MRD detection in ALL (ESG-MRD-ALL). Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007; 21: 604-611
• 18 van Dongen JJM, Seriu T, Panzer-Grümayer ER et al. Prognostic value of minimal residual disease in acute lymphoblastic leukemia in childhood. Lancet 1998; 352: 1731-1738
• 19 Yamada M, Hudson S, Tournay O et al. Detection of minimal disease in hematopoietic malignancies of the B-cell lineage by using third-complementarity-determining region (CDR-III)-specific probes. Proc Natl Acad Sci USA 1989; 86: 5123-5127